The combination of reduced-dose S1 and oxaliplatin (SOx) chemotherapy preserves quality of life (QoL) and physical function in vulnerable older patients with metastatic colorectal cancer (mCRC), according to a subgroup analysis of the NORDIC9* study presented at ESMO GI 2021.
Second-line treatment with tislelizumab improves overall survival (OS) in patients from Europe/North America (EU/NA) with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy, according to subgroup analysis of the RATIONALE 302* study presented at ESMO GI 2021.
Lenvatinib confers better clinical outcomes than sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) even when their liver function deteriorates to Child-Pugh B after initiation of treatment, according to a post hoc analysis of the REFLECT study.
In the final analysis of the phase IIIb PRECONNECT study presented at ESMO GI 2021, a chemotherapeutic regimen comprising trifluridine/tipiracil (FTD/TPI) continued to show favourable efficacy and safety for individuals with previously treated metastatic colorectal cancer (mCRC), with no new safety concerns.
Adding the VEGFR*-2 antagonist ramucirumab to paclitaxel extends survival of patients with advanced gastric/GEJ** adenocarcinoma compared with paclitaxel alone, regardless of liver metastasis status, according to a post hoc analysis of the RAINBOW*** trial presented at the ESMO GI 2021 Congress.
Adjuvant treatment with nab-paclitaxel and gemcitabine improved 5-year overall survival (OS) by over 4 months vs gemcitabine alone in patients with resected pancreatic cancer, an updated analysis of the phase III APACT* trial has shown.
Obese patients with colorectal cancer (CRC) may be receiving lower cumulative doses of chemotherapy than non-obese patients which may impact their survival outcomes, according to results of a study from the OCTOPUS consortium.
In a prespecified interim analysis of the phase III KEYNOTE-811 study presented at ESMO GI 2021, the addition of pembrolizumab to standard of care (SoC) first-line therapy comprising trastuzumab and chemotherapy led to a significant improvement in overall response rate (ORR) in previously untreated individuals with HER2-positive, metastatic gastric or gastroesophageal junction (G/GEJ) cancer.